secwatch.observer — SEC 8-K summary
======================================

Issuer:     Maze Therapeutics, Inc. (MAZE)
CIK:        0001842295
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001193125-25-193353
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Maze Therapeutics appoints Misbah Tahir as CFO, effective Sep 2, 2025
---------------------------------------------------------------------

- Misbah Tahir appointed CFO, previously CFO of IGM Biosciences (Jan 2019–Aug 2025).
- Annual base salary of $500,000, discretionary bonus up to 40% of base salary.
- One-time sign-on bonus of $50,000 (clawback if service <1 year) and option for 325,000 shares.
- Option vests 25% on first anniversary, then 1/48th monthly; severance includes 9 months base salary plus benefits.
- Enhanced severance on termination without cause or for good reason within 3 months before/12 months after change in control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842295/000119312525193353/0001193125-25-193353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842295/000119312525193353/d11864d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-193353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer